Buy Valeant Pharmaceuticals Intl Inc. Now, or You’ll Regret it Later

Valeant Pharmaceuticals Intl Inc.’s (TSX:VRX)(NYSE:VRX) stock rose over 9% following the release of its second-quarter earnings results. Will the rally continue?

| More on:
The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX), one of the largest specialty pharmaceutical companies in the world, announced better-than-expected second-quarter earnings results before the market opened on July 23, and its stock responded by rising over 9% in the trading session that followed.

Let’s take a closer look at the results to determine if we should consider buying in to this rally, or if we should wait for it to subside.

Surpassing analysts’ expectations with ease

Here’s a summary of Valeant’s second-quarter earnings results compared to what analysts had anticipated and its results in the same period a year ago.

Metric Reported Expected Year-Ago
Adjusted Earnings Per Share $2.56 $2.46 $1.91
Revenue $2.73 billion $2.54 billion $2.04 billion

Source: Thomson Reuters Corporation

Valeant’s adjusted earnings per share increased 34% and its revenue increased 33.9% compared to the second quarter of fiscal 2014. These very strong results can be primarily attributed to growth in the U.S. market, in which the company’s product sales soared 77.3% to $1.84 billion, driven by the strength in its dermatology, contact lenses, dental, and skin care product categories.

Here’s a quick breakdown of six other notable statistics from the report compared to the year-ago period:

  1. Product revenues increased 35.1% to $2.7 billion
  2. Other revenues decreased 20.4% to $37.4 million
  3. Adjusted net income increased 37.9% to $897.1 million
  4. Operating income decreased 3.8% to $341.5 million
  5. Net cash provided by operating activities increased 9.2% to $410.5 million
  6. Adjusted cash flow from operations increased 54.5% to $772.8 million

Valeant also raised its full-year outlook for fiscal 2015, calling for earnings per share in the range of $11.50-$11.80 and revenue in the range of $10.7 billion-$11.1 billion, compared to its previous outlook of earnings per share in the range of $10.90-$11.20 and revenue in the range of $10.4 billion-$10.6 billion.

Could Valeant’s stock head even higher?

It was a very strong quarter for Valeant, so I think its stock responded correctly by rallying over 9%. I also think the stock could continue higher from here, because it still trades at attractive forward valuations, including just 29.3 times its median earnings per share outlook of $11.65 for fiscal 2015 and only 22 times analysts’ estimated earnings per share of $15.49 for fiscal 2016, both of which are inexpensive compared to the industry average price-to-earnings multiple of 37.1 and its five-year average multiple of 159.6.

I think Valeant’s stock could consistently command a fair multiple of at least 35, which would place its shares upwards of $407 by the conclusion of fiscal 2015 and upwards of $542 by the conclusion of fiscal 2016, representing upside of more than 19% and 58%, respectively, from today’s levels.

With all of the information above in mind, I think Valeant Pharmaceuticals represents one of the best long-term growth opportunities in the market today, so Foolish investors should strongly consider beginning to scale in to positions.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Joseph Solitro has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Nuclear power station cooling tower
Metals and Mining Stocks

If You’d Invested $1,000 in Cameco Stock 5 Years Ago, This Is How Much You’d Have Now

Cameco (TSX:CCO) stock still looks undervalued, despite a 258% rally. Can the uranium miner deliver more capital gains to shareholders?

Read more »

Businessman holding tablet and showing a growing virtual hologram of statistics, graph and chart with arrow up on dark background. Stock market. Business growth, planning and strategy concept
Dividend Stocks

TFSA Magic: Earn Enormous Passive Income That the CRA Can’t Touch

If you're seeking out passive income, with zero taxes involved, then get on board with a TFSA and this portfolio…

Read more »

Man with no money. Businessman holding empty wallet
Dividend Stocks

2 Stocks Under $50 New Investors Can Confidently Buy

There are some great stocks under $50 that every investor needs to know about. Here’s a look at two great…

Read more »

potted green plant grows up in arrow shape
Stocks for Beginners

3 Growth Stocks I’m Buying in April

These three growth stocks are up in the last year, and that is likely to continue on as we keep…

Read more »

clock time
Tech Stocks

Long-Term Investing: 3 Top Canadian Stocks You Can Buy for Under $20 a Share

These three under-$20 stocks offer excellent buying opportunities for long-term investors.

Read more »

Arrowings ascending on a chalkboard
Energy Stocks

Beat the TSX With This Cash-Gushing Dividend Stock

Canadian Natural Resources stock is well set up to beat the TSX as it continues to generate strong cash flows…

Read more »

think thought consider
Dividend Stocks

Down 10.88%: Is ATD Stock a Good Buy After Earnings?

Alimentation Couche-Tard (TSX:ATD) stock might not be the easy buy-case it once was. Here’s a look at what happened.

Read more »

money cash dividends
Dividend Stocks

TFSA Dividend Stocks: Earn $1,200/Year Tax-Free

Canadian stocks like Fortis are a must-have in your portfolio to earn tax-free yields for decades.

Read more »